Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system

Douglas G. Widman, Tomohiro Ishikawa, Rafik Fayzulin, Nigel Bourne, Peter W. Mason

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Safer vaccines are needed to prevent flavivirus diseases. To help develop these products we have produced a pseudoinfectious West Nile virus (WNV) lacking a functional C gene which we have named RepliVAX WN. Here we demonstrate that RepliVAX WN can be safely propagated at high titer in BHK cells and vaccine-certified Vero cells engineered to stably express the C protein needed to trans-complement RepliVAX WN growth. Using these BHK cells we selected a better growing mutant RepliVAX WN population and used this to generate a second-generation RepliVAX WN (RepliVAX WN.2). RepliVAX WN.2 grown in these C-expressing cell lines safely elicit strong protective immunity against WNV disease in mice and hamsters. Taken together, these results indicate the clinical utility of RepliVAX WN.2 as a vaccine candidate against West Nile encephalitis.

Original languageEnglish (US)
Pages (from-to)2762-2771
Number of pages10
JournalVaccine
Volume26
Issue number22
DOIs
StatePublished - May 23 2008

Fingerprint

West Nile Virus Vaccines
West Nile virus
Vaccines
vaccines
Flavivirus
Vero Cells
Virus Diseases
cells
Encephalitis
encephalitis
Protein C
hamsters
Cricetinae
Immunity
complement
immunity
cell lines
Cell Line
mutants
mice

Keywords

  • Single-cycle virus
  • Subviral particles
  • West Nile virus

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. / Widman, Douglas G.; Ishikawa, Tomohiro; Fayzulin, Rafik; Bourne, Nigel; Mason, Peter W.

In: Vaccine, Vol. 26, No. 22, 23.05.2008, p. 2762-2771.

Research output: Contribution to journalArticle

Widman, Douglas G. ; Ishikawa, Tomohiro ; Fayzulin, Rafik ; Bourne, Nigel ; Mason, Peter W. / Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. In: Vaccine. 2008 ; Vol. 26, No. 22. pp. 2762-2771.
@article{a5ca6a5059494051b8120045983f137f,
title = "Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system",
abstract = "Safer vaccines are needed to prevent flavivirus diseases. To help develop these products we have produced a pseudoinfectious West Nile virus (WNV) lacking a functional C gene which we have named RepliVAX WN. Here we demonstrate that RepliVAX WN can be safely propagated at high titer in BHK cells and vaccine-certified Vero cells engineered to stably express the C protein needed to trans-complement RepliVAX WN growth. Using these BHK cells we selected a better growing mutant RepliVAX WN population and used this to generate a second-generation RepliVAX WN (RepliVAX WN.2). RepliVAX WN.2 grown in these C-expressing cell lines safely elicit strong protective immunity against WNV disease in mice and hamsters. Taken together, these results indicate the clinical utility of RepliVAX WN.2 as a vaccine candidate against West Nile encephalitis.",
keywords = "Single-cycle virus, Subviral particles, West Nile virus",
author = "Widman, {Douglas G.} and Tomohiro Ishikawa and Rafik Fayzulin and Nigel Bourne and Mason, {Peter W.}",
year = "2008",
month = "5",
day = "23",
doi = "10.1016/j.vaccine.2008.03.009",
language = "English (US)",
volume = "26",
pages = "2762--2771",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system

AU - Widman, Douglas G.

AU - Ishikawa, Tomohiro

AU - Fayzulin, Rafik

AU - Bourne, Nigel

AU - Mason, Peter W.

PY - 2008/5/23

Y1 - 2008/5/23

N2 - Safer vaccines are needed to prevent flavivirus diseases. To help develop these products we have produced a pseudoinfectious West Nile virus (WNV) lacking a functional C gene which we have named RepliVAX WN. Here we demonstrate that RepliVAX WN can be safely propagated at high titer in BHK cells and vaccine-certified Vero cells engineered to stably express the C protein needed to trans-complement RepliVAX WN growth. Using these BHK cells we selected a better growing mutant RepliVAX WN population and used this to generate a second-generation RepliVAX WN (RepliVAX WN.2). RepliVAX WN.2 grown in these C-expressing cell lines safely elicit strong protective immunity against WNV disease in mice and hamsters. Taken together, these results indicate the clinical utility of RepliVAX WN.2 as a vaccine candidate against West Nile encephalitis.

AB - Safer vaccines are needed to prevent flavivirus diseases. To help develop these products we have produced a pseudoinfectious West Nile virus (WNV) lacking a functional C gene which we have named RepliVAX WN. Here we demonstrate that RepliVAX WN can be safely propagated at high titer in BHK cells and vaccine-certified Vero cells engineered to stably express the C protein needed to trans-complement RepliVAX WN growth. Using these BHK cells we selected a better growing mutant RepliVAX WN population and used this to generate a second-generation RepliVAX WN (RepliVAX WN.2). RepliVAX WN.2 grown in these C-expressing cell lines safely elicit strong protective immunity against WNV disease in mice and hamsters. Taken together, these results indicate the clinical utility of RepliVAX WN.2 as a vaccine candidate against West Nile encephalitis.

KW - Single-cycle virus

KW - Subviral particles

KW - West Nile virus

UR - http://www.scopus.com/inward/record.url?scp=43049178346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049178346&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.03.009

DO - 10.1016/j.vaccine.2008.03.009

M3 - Article

VL - 26

SP - 2762

EP - 2771

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -